Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 14-Month, Randomized, Double-Blind,Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety of CP-945,598 In Prevention Of Weight Regain In Obese Subjects

NCT00483171 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00483171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00483171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 14-Month, Randomized, Double-Blind,Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety of CP-945,598 In Prevention Of Weight Regain In Obese Subjects
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2008
Completion date
January 31, 2009
Enrollment
699 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

obesity